AZ’s Imfinzi: significant OS in Stage III nsclc
This announcement contains inside information 25 May 2018 07:00 BST Imfinzi significantly improves overall survival in the Phase IIIPACIFIC trial for unresectable Stage III non-small cell lung cancer Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-